NIKA PHARMACEUTICALS, INC Quarterly Debt-to-equity in % from Q3 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Nika Pharmaceuticals, Inc quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2024.
  • Nika Pharmaceuticals, Inc Debt-to-equity for the quarter ending September 30, 2024 was -170 %, a 48.8% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -170 -55.6 -48.8% Sep 30, 2024
Q2 2024 -187 -70.6 -60.5% Jun 30, 2024
Q1 2024 -119 +15.3 +11.4% Mar 31, 2024
Q4 2023 -118 Dec 31, 2023
Q3 2023 -114 Sep 30, 2023
Q2 2023 -117 Jun 30, 2023
Q1 2023 -134 Mar 31, 2023
Q4 2021 -105 Dec 31, 2021
Q3 2021 -108 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.